Updates

** Shares of Australia's CSL CSL.AX down as much as 6% to A$94.760, on track for their fourth consecutive session of losses, if current trends hold

** Citi downgrades company's rating to "neutral" from "buy", cuts target price to A$110 from A$200

** Citi downbeat on CSL, says investors will be cautious; trims NPATA estimates by 10% in FY26

** Analysts at Morningstar slash revenue and underlying NPAT forecasts for biotech firm by 3% and 9%, respectively, on average over next 10 years

** Says it was hard to justify high revenue growth for CSL, given lack of sales momentum

** On Monday, Australia's CSL cut its annual profit forecast and warned of a $5 billion impairment

** The investment research firm says "hiring credible new CEO and unveiling a compelling vision will be important steps on the path to redemption"

** Nine of 16 analysts rate the stock "buy" or higher, seven "hold"; their median PT is A$195 – data compiled by LSEG

** YTD, stock down 44.1% including day's moves